5 Stocks That May Be Splitting Soon

4. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Number of Hedge Fund Holders: 44

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a leading global biotechnology company that discovers, develops, manufactures, and commercializes medicines for treating various diseases. The company has a strong pipeline of products in various stages of development, including treatments for age-related macular degeneration, non-alcoholic steatohepatitis, atopic dermatitis, and psoriasis.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the companies whose stock split is long overdue. The company has never split its stock in history and, as of November 9, is trading at $743 per share. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is ranked high among the stocks that may split soon.

On November 9, Truist Securities analyst Robyn Karnauskas raised his price target on Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to $856 from $790 and maintained a Buy rating on the shares.

At the end of Q2 2022, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was a part of 44 investors’ portfolios that held positions worth $1.60 billion in the company. As of June 30, Renaissance Technologies is the top investor in the company and holds a position worth $344.6 million.

Here is what Bronte Capital had to say about Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in its third-quarter 2022 investor letter:

“There have been some bright spots in our long book. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), a major position and a stock we wrote up in our June 2021 letter, has been one of the best performing stocks in the S&P 500 this year. Alas it has not been enough to offset some of our weaker stocks, let alone our overweight exposure to the UK (and Europe) which have suffered from both stock and currency weakness. We do not think we are bad at picking stocks on the long side and hope – reasonably we think – for better relative results in the future. Prior to COVID, our longs were markedly better than the index. Unfortunately, if you look at our long book this quarter and since the onset of the COVID pandemic, there is scant evidence that we have added any value by picking stocks to go long.”